Luke Child Dabin

Dr. Luke Child Dabin

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2021 in Science Advances
Verified
Journal Article
Open access
HKHande Karahan
Hande Karahan
DSDaniel C. Smith
Daniel C. Smith
BKByungwook Kim
Byungwook Kim
LDLuke Child Dabin
Luke Child Dabin
MAMamun Al-Amin
Mamun Al-Amin
Jungsu KimJungsu Kim
Jungsu Kim
A cytoskeleton-associated protein regulates microglial function and affects Alzheimer’s disease phenotypes.

11 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
BKByungwook Kim
Byungwook Kim
LDLuke Child Dabin
Luke Child Dabin
MTMason Douglas Tate
Mason Douglas Tate
HKHande Karahan
Hande Karahan
ASAhmad Daniel Sharify
Ahmad Daniel Sharify
Jungsu KimJungsu Kim
Jungsu Kim
SPI1 was recently reported as a genetic risk factor for Alzheimer’s disease (AD) in large-scale genome-wide association studies. However, it is unknown whether SPI1 should be downregulated or increased to have therapeutic benefits. To investigate the effect of modulating SPI1 levels on AD pathogenesis, we performed extensive biochemical, histological, and transcriptomic analyses using both Spi1-knockdown and Spi1-overexpression mouse models. Here, we show that the knockdown of Spi1 expression significantly exacerbates insoluble amyloid-β (Aβ) levels, amyloid plaque deposition, and gliosis. Conversely, overexpression of Spi1 significantly ameliorates these phenotypes and dystrophic neurites. Further mechanistic studies using targeted and single-cell transcriptomics approaches demonstrate that altered Spi1 expression modulates several pathways, such as immune response pathways and complement system. Our data suggest that transcriptional reprogramming by targeting transcription factors, like Spi1, might hold promise as a therapeutic strategy. This approach could potentially expand the current landscape of druggable targets for AD.

12 September 2020 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
LDLuke Child Dabin
Luke Child Dabin
FGFernando Guntoro
Fernando Guntoro
TCTracy Campbell
Tracy Campbell
TBTony Bélicard
Tony Bélicard
ASAdam R. Smith
Adam R. Smith
EVEmmanuelle Viré
Emmanuelle Viré
Prion diseases are fatal and transmissible neurodegenerative disorders caused by the misfolding and aggregation of prion protein. Although recent studies have implicated epigenetic variation in common neurodegenerative disorders, no study has yet explored their role in human prion diseases. Here we profiled genome-wide blood DNA methylation in the most common human prion disease, sporadic Creutzfeldt–Jakob disease (sCJD). Our case–control study (n = 219), when accounting for differences in cell type composition between individuals, identified 38 probes at genome-wide significance (p < 1.24 × 10–7). Nine of these sites were taken forward in a replication study, performed in an independent case–control (n = 186) cohort using pyrosequencing. Sites in or close to FKBP5, AIM2 (2 probes), UHRF1, KCNAB2 successfully replicated. The blood-based DNA methylation signal was tissue- and disease-specific, in that the replicated probe signals were unchanged in case–control studies using sCJD frontal-cortex (n = 84), blood samples from patients with Alzheimer’s disease, and from inherited and acquired prion diseases. Machine learning algorithms using blood DNA methylation array profiles accurately distinguished sCJD patients and controls. Finally, we identified sites whose methylation levels associated with prolonged survival in sCJD patients. Altogether, this study has identified a peripheral DNA methylation signature of sCJD with a variety of potential biomarker applications.

7 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
PNPenny J. Norsworthy
Penny J. Norsworthy
ATAndrew G. B. Thompson
Andrew G. B. Thompson
TMTze H. Mok
Tze H. Mok
FGFernando Guntoro
Fernando Guntoro
LDLuke Child Dabin
Luke Child Dabin
EVEmmanuelle A. Viré
Emmanuelle A. Viré
Sporadic Creutzfeldt-Jakob disease (sCJD) presents as a rapidly progressive dementia which is usually fatal within six months. No clinical blood tests are available for diagnosis or disease monitoring. Here, we profile blood microRNA (miRNA) expression in sCJD. Sequencing of 57 sCJD patients, and healthy controls reveals differential expression of hsa-let-7i-5p, hsa-miR-16-5p, hsa-miR-93-5p and hsa-miR-106b-3p. Downregulation of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p replicates in an independent cohort using quantitative PCR, with concomitant upregulation of four mRNA targets. Absence of correlation in cross-sectional analysis with clinical phenotypes parallels the lack of association between rate of decline in miRNA expression, and rate of disease progression in a longitudinal cohort of samples from 21 patients. Finally, the miRNA signature shows a high level of accuracy in discriminating sCJD from Alzheimer’s disease. These findings highlight molecular alterations in the periphery in sCJD which provide information about differential diagnosis and improve mechanistic understanding of human prion diseases.

10 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
ALAudrey Lee-Gosselin
Audrey Lee-Gosselin
NJNur Jury-Garfe
Nur Jury-Garfe
YYYanwen You
Yanwen You
LDLuke Child Dabin
Luke Child Dabin
DSDisha Soni
Disha Soni
CLCristian Lasagna-Reeves
Cristian Lasagna-Reeves
The role of TREM2 in Alzheimer’s disease (AD) is not fully understood. Previous studies investigating the effect of TREM2 deletion on tauopathy mouse models without the contribution of b-amyloid have focused only on tau overexpression models. Herein, we investigated the effects of TREM2 deficiency on tau spreading using a mouse model in which endogenous tau is seeded to produce AD-like tau features. We found that Trem2−/− mice exhibit attenuated tau pathology in multiple brain regions concomitant with a decreased microglial density. The neuroinflammatory profile in TREM2-deficient mice did not induce an activated inflammatory response to tau pathology. These findings suggest that reduced TREM2 signaling may alter the response of microglia to pathological tau aggregates, impairing their activation and decreasing their capacity to contribute to tau spreading. However, caution should be exercised when targeting TREM2 as a therapeutic entry point for AD until its involvement in tau aggregation and propagation is better understood.

22 August 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DADominic J. Acri
Dominic J. Acri
YYYanwen You
Yanwen You
MTMason D. Tate
Mason D. Tate
HKHande Karahan
Hande Karahan
PMPablo Martinez
Pablo Martinez
Jungsu KimJungsu Kim
Jungsu Kim
Previous research demonstrated that genetic heterogeneity is a critical factor in modeling amyloid accumulation and other Alzheimer’s disease phenotypes. However, it is unknown what mechanisms underlie these effects of genetic background on modeling tau aggregate-driven pathogenicity. In this study, we induced tau aggregation in wild-derived mice by expressing MAPT. To investigate the effect of genetic background on the action of tau aggregates, we performed RNA sequencing with brains of C57BL/6J, CAST/EiJ, PWK/PhJ, and WSB/EiJ mice (n = 64) and determined core transcriptional signature conserved in all genetic backgrounds and signature unique to wild-derived backgrounds. By measuring tau seeding activity using the cortex, we identified 19 key genes associated with tau seeding and amyloid response. Interestingly, microglial pathways were strongly associated with tau seeding activity in CAST/EiJ and PWK/PhJ backgrounds. Collectively, our study demonstrates that mouse genetic context affects tau-mediated alteration of transcriptome and tau seeding. The gene modules associated with tau seeding provide an important resource to better model tauopathy.